Bibliography
- PALELLA FJ Jr, DELANEY KM, AC et al: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. New EngL J. Med. (1998) 338(13):853–860.
- ••Seminal paper on the change in the HIVepidemic after the introduction of protease inhibitors.
- HOGG RS, HEATH KV, YIP B et al.: Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA (1998) 279(6):450–454.
- •Important paper on the change in the outcome of HIV-infected individuals in Canada.
- MOCROFT A, KATLAMA C, AM et al.: AIDS across Europe, 1994-1998: the EuroSIDA study. Lancet(2000) 356(9226):291–296.
- •Important paper on the change in the outcome of HIV-infected individuals in Europe.
- PATERSON DL, SWINDELL S, MOHRJ et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. (2000) 133(1):21–30.
- STONE VE, CLARKE J, LOVELL J et al: HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors. J. Gen. Intern. Med. (1998) 13(9):586–593.
- WILLIAMS A, FRIEDLAND G: Adherence, compliance and HAART. AIDS Clin. Care (1997) 9(7):51–58.
- YEH KC, DEUTSCH PJ, HADDIX H et al.: Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob. Agents Chemother: (1998) 42 (2):332–338.
- D'AQUILA RT, SHAPIRO JM, BRUN-VEZINET F et al.: Drug resistance mutations in HIV-1. Topics HIV Med. (2002) 10(5):11–15.
- ••Updated version of HIV-related drug.
- DREYER GB, BOEHM JC, CHENERA B et al: A symmetric inhibitor binds HIV-1 protease asymmetrically. Biochemistry (1993) 32(3):937–947.
- MILLER M, SCHNEIDER J, BK et al.: Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. Science (1989) 246(4934):1149–1152.
- LAMBERT DM, PETTE WAY SR Jr, MCDANAL CE et al.: Human immunodeficiency virus Type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells. Antimicrob. Agents Chemother: (1992) 36(5):982–988.
- RUSCONI S, LA SETA CATAMANCIO S: HIV-1 protease inhibitors in development. Expert Opin. Investig. Drugs (2002) 11(3):387–395.
- HIRSCH MS, BRUN-VEZINET F, D'AQUILA RT et al.: Antiretroviral drug resistance testing in adult HIV-1 infection. Recommendations of an International AIDS Society panel. JAMA (2000) 283(18):2417–2426.
- ••Seminal paper describing the rationale of resistance testing.
- YENI PG, HAMMER SM, CC et al: Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the AIDS Society-USA panel. JAMA (2002) 288(2):222–235.
- ••Updated information on antiretroviral during the different stages of HIV infection.
- CASINI A, SCOZZAFAVA A, SUPURAN CT: Sulfonamide derivatives protease inhibitory action as anticancer, anti-inflammatory and antiviral agents. Expert Opin. Ther. Patents (2002) 12(9):1307–1327.
- ••A very good review describing sulfonamidederivatives in different scenarios.
- PIOT P, BARTOS M, GHYS PD, WALKER N, SCHWARTLANDER B: The global impact of HIV/AIDS. Nature (2001) 410(6831):968–973.
- ••Important review on the global status of the epidemic.